Polyfunctionality of broadly neutralizing HIV-1 antibodies.
Journal
Current opinion in HIV and AIDS
ISSN: 1746-6318
Titre abrégé: Curr Opin HIV AIDS
Pays: United States
ID NLM: 101264945
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
medline:
7
6
2023
pubmed:
30
5
2023
entrez:
30
5
2023
Statut:
ppublish
Résumé
The discovery of broadly neutralizing HIV-1 antibodies (bNAbs) has provided a framework for vaccine design and created new hope toward an HIV-1 cure. These antibodies recognize the HIV-1 Envelope and inhibit viral fusion with unprecedented breadth and potency. Beyond their unique neutralization capacity, bNAbs also activate immune cells and interfere with viral spread through nonneutralizing activities. Here, we review the landscape of bNAbs functions and their contribution to clinical efficacy. Parallel evaluation of bNAbs nonneutralizing activities using in vivo and in vitro models have revealed how their importance varies across antibodies and strains. Nonneutralizing bNAbs functions target both infected cells and viral particles, leading to their destruction through various mechanisms. Reservoir targeting and prevention in context of suboptimal neutralization highly depends on bNAbs polyfunctionality. We recently showed that bNAbs tether virions at the surface of infected cells, impairing release and forming immune complexes, with consequences that are still to be understood. Nonneutralizing activities of bNAbs target infected cells, virions, and immune complexes, promoting viral clearance and possibly improving immune responses. We review how these functions participate to the efficacy of bNAbs and how they can be manipulated to improve bNAbs therapies.
Identifiants
pubmed: 37249912
doi: 10.1097/COH.0000000000000799
pii: 01222929-202307000-00005
doi:
Substances chimiques
Broadly Neutralizing Antibodies
0
HIV Antibodies
0
Antibodies, Neutralizing
0
Antigen-Antibody Complex
0
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
178-183Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Stephenson KE, Wagh K, Korber B, Barouch DH. Vaccines and broadly neutralizing antibodies for HIV-1 prevention. Annu Rev Immunol 2020; 38:673–703.
Mendoza P, Gruell H, Nogueira L, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 2018; 561:479–484.
Bar KJ, Sneller MC, Harrison LJ, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. New Engl J Med 2016; 375:2037–2050.
Corey L, Gilbert PB, Juraska M, et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. New Engl J Med 2021; 384:1003–1014.
Gaebler C, Nogueira L, Stoffel E, et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature 2022; 606:368–374.
Gunst JD, Pahus MH, Rosás-Umbert M, et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial. Nat Med 2022; 28:2424–2435.
Rosás-Umbert M, Gunst JD, Pahus MH, et al. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity. Nat Commun 2022; 13:6473.
Sneller MC, Blazkova J, Justement JS, et al. Combination anti-HIV antibodies provide sustained virological suppression. Nature 2022; 606:375–381.
Bournazos S, Klein F, Pietzsch J, et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 2014; 158:1243–1253.
Horwitz JA, Bar-On Y, Lu C-L, et al. Nonneutralizing antibodies alter the course of HIV-1 infection in vivo. Cell 2017; 170:637.e10–648.e10.
Parsons MS, Lee WS, Kristensen AB, et al. Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. J Clin Invest 2018; 129:182–191.
Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101–104.
Asokan M, Dias J, Liu C, et al. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proc Natl Acad Sci USA 2020; 117:18754–18763.
Bournazos S, Wang TT, Dahan R, et al. Signaling by antibodies: recent progress. Annu Rev Immunol 2017; 35:285–311.
Jennewein MF, Alter G. The immunoregulatory roles of antibody glycosylation. Trends Immunol 2017; 38:358–372.
Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol 2018; 18:46–61.
Ferrari G, Pollara J, Kozink D, et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011; 85:7029–7036.
Richard J, Prévost J, Alsahafi N, et al. Impact of HIV-1 envelope conformation on ADCC responses. Trends Microbiol 2018; 26:253–265.
Bruel T, Guivel-Benhassine F, Amraoui S, et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun 2016; 7:10844.
Bredow B von, Arias JF, Heyer LN, et al. Comparison of antibody-dependent cell-mediated cytotoxicity and virus neutralization by HIV-1 Env-specific monoclonal antibodies. J Virol 2016; 90:6127–6139.
Bruel T, Guivel-Benhassine F, Lorin V, et al. Lack of ADCC breadth of human nonneutralizing anti-HIV-1 antibodies. J Virol 2017; 91:e02440-16.
Ren Y, Korom M, Truong R, et al. Susceptibility to neutralization by broadly neutralizing antibodies generally correlates with infected cell binding for a panel of clade B HIV reactivated from latent reservoirs. J Virol 2018; 92:e00895-18.
Dufloo J, Guivel-Benhassine F, Buchrieser J, et al. Anti HIV -1 antibodies trigger nonlytic complement deposition on infected cells. Embo Rep 2019; 21:e49351.
Diebolder CA, Beurskens FJ, Jong RN de, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014; 343:1260–1263.
Pedersen ML, Pedersen DV, Winkler MBL, et al. Nanobody-mediated complement activation to kill HIV-infected cells. Embo Mol Med 2023; 15:e16422.
West EE, Kolev M, Kemper C. Complement and the regulation of T cell responses. Annu Rev Immunol 2018; 36:309–338.
Triantafilou K, Hughes TR, Triantafilou M, Morgan BP. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J Cell Sci 2013; 126:2903–2913.
Sips M, Krykbaeva M, Diefenbach TJ, et al. Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies. Mucosal Immunol 2016; 9:1584–1595.
Gach JS, Bouzin M, Wong MP, et al. Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis. PLoS Pathog 2017; 13:e1006793.
Richard J, Prévost J, Baxter AE, et al. Uninfected bystander cells impact the measurement of HIV-specific antibody-dependent cellular cytotoxicity responses. Mbio 2018; 9:e00358–e418.
Clayton KL, Mylvaganam G, Villasmil-Ocando A, et al. HIV-infected macrophages resist efficient NK cell-mediated killing while preserving inflammatory cytokine responses. Cell Host Microbe 2021; 29:435–447. e9.
Astorga-Gamaza A, Buzon MJ. The active human immunodeficiency virus reservoir during antiretroviral therapy: emerging players in viral persistence. Curr Opin Hiv Aids 2021; 16:193–199.
Stoermer KA, Morrison TE. Complement and viral pathogenesis. Virology 2011; 411:362–373.
Huber M, Fischer M, Misselwitz B, et al. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. Plos Med 2006; 3:e441.
Saifuddin M, Parker CJ, Peeples ME, et al. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 1995; 182:501–509.
Spencer DA, Goldberg BS, Pandey S, et al. Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis. Nat Commun 2022; 13:662.
Goldberg BS, Kaku CI, Dufloo J, et al. Revisiting an IgG Fc loss-of-function experiment: the role of complement in HIV broadly neutralizing antibody b12 activity. Mbio 2021; 12:e01743–e1821.
Gach JS, Matsuno SY, Mercado M, et al. Internalization of HIV-1 by phagocytes is increased when virions are opsonized with multimeric antibody in the presence of complement. J Virol 2021; 96:e01689–e1721.
Musich T, Li L, Liu L, et al. Monoclonal antibodies specific for the V2, V3, CD4-binding site, and gp41 of HIV-1 mediate phagocytosis in a dose-dependent manner. J Virol 2017; 91:e02325–e2416.
Tay MZ, Wiehe K, Pollara J. Antibody-dependent cellular phagocytosis in antiviral immune responses. Front Immunol 2019; 10:332.
Jin J, Galaz-Montoya JG, Sherman MB, et al. Neutralizing antibodies inhibit chikungunya virus budding at the plasma membrane. Cell Host Microbe 2018; 24:417–428. e5.
Kajihara M, Marzi A, Nakayama E, et al. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J Virol 2012; 86:13467–13474.
Bangaru S, Zhang H, Gilchuk IM, et al. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nat Commun 2018; 9:2669.
Dufloo J, Planchais C, Frémont S, et al. Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells. Nat Commun 2022; 13:630.
Neil SJD, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451:425–430.
Tipoe T, Fidler S, Frater J. An exploration of how broadly neutralizing antibodies might induce HIV remission: the ‘vaccinal’ effect. Curr Opin HIV AIDS 2022; 17:162–170.
Stieh DJ, King DF, Klein K, et al. Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology 2014; 11:78.
Galão RP, Le Tortorec A, Pickering S, et al. Innate sensing of HIV-1 assembly by tetherin induces NFκB-dependent proinflammatory responses. Cell Host Microbe 2012; 12:633–644.
Pyzik M, Kozicky LK, Gandhi AK, Blumberg RS. The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol 2023; 1–18. doi:10.1038/s41577-022-00821-1.
doi: 10.1038/s41577-022-00821-1
Qi T, Cao Y. In translation: FcRn across the therapeutic spectrum. Int J Mol Sci 2021; 22:3048.
Gautam R, Nishimura Y, Gaughan N, et al. A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. Nat Med 2018; 24:610–616.
Gaudinski MR, Coates EE, Houser KV, et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults. PLoS Med 2018; 15:e1002493.
Wang W, Lu P, Fang Y, et al. Monoclonal antibodies with identical fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011; 39:1469–1477.
Ko S-Y, Pegu A, Rudicell RS, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 2014; 514:642–645.
Li Z, Palaniyandi S, Zeng R, et al. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci USA 2011; 108:4388–4393.
Hubbard JJ, Pyzik M, Rath T, et al. FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity. J Exp Med 2020; 217:e20200359.
Qiao S-W, Kobayashi K, Johansen F-E, et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci USA 2008; 105:9337–9342.